Giorgio Vittorio Scagliotti

Summary

Affiliation: University of Torino
Country: Italy

Publications

  1. ncbi Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Turin
    J Clin Oncol 20:4285-91. 2002
  2. ncbi Proteasome inhibitors in lung cancer
    Giorgio Scagliotti
    University of Torino, Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital Regione Gonzole 10, 10043 Orbassano, Torino, Italy
    Crit Rev Oncol Hematol 58:177-89. 2006
  3. ncbi Multidrug resistance in non-small-cell lung cancer
    G V Scagliotti
    University of Turin, Department of Clinical and Biological Sciences, Azienda Ospedaliera S Luigi Orbassano, Torino, Italy
    Ann Oncol 10:S83-6. 1999
  4. ncbi Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, S Luigi Gonzaga Hospital, University of Torino, Regione Gonzole 10 00043 Orbassano, Turin, Italy
    Clin Cancer Res 11:690-6. 2005
  5. ncbi Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy
    S Novello
    Department of Clinical and Biological Sciences, University of Torino, Turin, Italy
    Lung Cancer 48:379-87. 2005
  6. ncbi International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1
    Giorgio V Scagliotti
    University of Turin, S Luigi Hospital, Turin, Italy
    J Clin Oncol 30:2829-36. 2012
  7. ncbi Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedliera S Luigi, Orbassano, Italy
    Lung Cancer 25:39-46. 1999
  8. ncbi Adjuvant chemotherapy after complete resection for early stage NSCLC
    Giorgio Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedaliera S Luigi, Thoracic Oncology Unit, Orbassano, Torino, Italy
    Lung Cancer 42:S47-51. 2003
  9. ncbi Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences and Department of Radiotherapy, University of Torino, S Luigi Hospital, Regione Gonzole 10, Orbassano, Turin 10043, Italy
    Br J Cancer 94:1375-82. 2006
  10. ncbi Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer
    Giorgio Scagliotti
    Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Regione Gonzole 10, Orbassano, Torino, Italy 10043
    J Clin Oncol 28:1835-42. 2010

Detail Information

Publications43

  1. ncbi Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Turin
    J Clin Oncol 20:4285-91. 2002
    ..To evaluate whether two commonly used newer platinum-based regimens offer any advantage over vinorelbine-cisplatin (reference regimen) in response rate for patients with advanced non-small-cell lung cancer (NSCLC)...
  2. ncbi Proteasome inhibitors in lung cancer
    Giorgio Scagliotti
    University of Torino, Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital Regione Gonzole 10, 10043 Orbassano, Torino, Italy
    Crit Rev Oncol Hematol 58:177-89. 2006
    ..Numerous preclinical and clinical studies are ongoing in both NSCLC and SCLC. Proteasome inhibition could potentially play a significant role in the future management of these conditions...
  3. ncbi Multidrug resistance in non-small-cell lung cancer
    G V Scagliotti
    University of Turin, Department of Clinical and Biological Sciences, Azienda Ospedaliera S Luigi Orbassano, Torino, Italy
    Ann Oncol 10:S83-6. 1999
    ..In lung cancer the role of the different forms of multidrug resistance is complex and only partially understood...
  4. ncbi Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, S Luigi Gonzaga Hospital, University of Torino, Regione Gonzole 10 00043 Orbassano, Turin, Italy
    Clin Cancer Res 11:690-6. 2005
    ..To determine efficacy and toxicity of two pemetrexed-based regimens in chemonaive patients with locally advanced or metastatic non-small cell lung cancer...
  5. ncbi Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy
    S Novello
    Department of Clinical and Biological Sciences, University of Torino, Turin, Italy
    Lung Cancer 48:379-87. 2005
    ..Based on resource consumption in a clinical trial, Gem/Cis had the lowest overall mean costs of the three chemotherapy regimens. Gem/Cis therefore has the potential to save costs in the treatment of advanced NSCLC in Italy...
  6. ncbi International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1
    Giorgio V Scagliotti
    University of Turin, S Luigi Hospital, Turin, Italy
    J Clin Oncol 30:2829-36. 2012
    ....
  7. ncbi Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedliera S Luigi, Orbassano, Italy
    Lung Cancer 25:39-46. 1999
    ....
  8. ncbi Adjuvant chemotherapy after complete resection for early stage NSCLC
    Giorgio Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedaliera S Luigi, Thoracic Oncology Unit, Orbassano, Torino, Italy
    Lung Cancer 42:S47-51. 2003
    ..Data regarding large-scale adjuvant chemotherapy trials, closed for the accrual almost four to five years ago, will be fully available soon and, hopefully, a specific meta-analysis will be performed...
  9. ncbi Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences and Department of Radiotherapy, University of Torino, S Luigi Hospital, Regione Gonzole 10, Orbassano, Turin 10043, Italy
    Br J Cancer 94:1375-82. 2006
    ..Docetaxel-cisplatin induction therapy followed by concurrent docetaxel and thoracic radiotherapy is a feasible treatment option, showing good clinical activity and tolerability, for locally advanced NSCLC...
  10. ncbi Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer
    Giorgio Scagliotti
    Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Regione Gonzole 10, Orbassano, Torino, Italy 10043
    J Clin Oncol 28:1835-42. 2010
    ..4%), hand-foot skin reaction (7.8%), and diarrhea (3.5%). CONCLUSION No clinical benefit was observed from adding sorafenib to CP chemotherapy as first-line treatment for NSCLC...
  11. ncbi An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer
    Giorgio Scagliotti
    Department of Clinical and Biological Sciences Head, Luigi Hospital Regione Gonzole 10, University of Torino, 10043 Orbassano, Turin, Italy
    Expert Opin Pharmacother 6:2855-66. 2005
    ..For patients with advanced recurrent NSCLC and good performance status who progress after first-line chemotherapy, pemetrexed should be considered as a new standard of care...
  12. ncbi Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, San Luigi Hospital, Regione Gonzole, 10 Orbassano, Torino 10043, Italy
    Eur J Cancer 45:2298-303. 2009
    ..The current analysis characterised the clinical benefit (i.e. survival) relative to clinical risk (i.e. drug-related toxicity) of the doublets...
  13. ncbi Pemetrexed and its emerging role in the treatment of thoracic malignancies
    Giorgio V Scagliotti
    University of Torino, Department of Clinical and Biological Sciences, S Luigi Hospital Thoracic Oncology Unit, Regione Gonzole 10 10043 Orbassano, Turin, Italy
    Expert Opin Investig Drugs 12:853-63. 2003
    ..Here, the current data for pemetrexed in treating thoracic malignancies are reviewed, with special focus on malignant pleural mesothelioma and non-small cell lung cancer...
  14. ncbi Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma
    Giorgio V Scagliotti
    University of Turin, Department of Clinical and Biological Sciences, Azienda Ospedaliera S Luigi, Regione Gonzole 10, 10043 Orbassano Torino Italy
    J Clin Oncol 21:1556-61. 2003
    ..This phase II clinical study evaluated the efficacy of pemetrexed for the treatment of malignant pleural mesothelioma (MPM)...
  15. ncbi Consensus development conference on the medical treatment of non-small cell lung cancer: treatment of the early stages
    Giorgio Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedaliera S Luigi, Orbassano, Torino, Italy
    Lung Cancer 38:S23-9. 2002
    ..Several randomised trials are currently ongoing. In the next future the role of targeted biological therapies as agents acting on minimal residual disease should be explored...
  16. ncbi Gemcitabine (Gemzar)-based induction chemotherapy in non-small-cell lung cancer
    Giorgio Vittorio Scagliotti
    Thoracic Oncology Unit, Department of Clinical and Biological Sciences, S Luigi Hospital, University of Torino, Orbassano, Turin, Italy
    Lung Cancer 38:S13-9. 2002
    ....
  17. ncbi Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project
    L Crino
    Department of Medical Oncology, Policlinico Hospital, Perugia, Italy
    J Clin Oncol 17:3522-30. 1999
    ..The end points were the evaluation of quality of life (QoL), response rates, survival, and toxicity...
  18. ncbi Role of erythropoietin in the treatment of lung cancer associated anaemia
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Regione Gonzole 10, Azienda Ospedaliera S Luigi, 10043 Orbassano, Torino, Italy
    Lung Cancer 34:S91-4. 2001
    ..This 'functional' level would be in keeping with the body's physiological erythropoietin response...
  19. ncbi Gemcitabine/cisplatin as induction therapy for stage IIIA N2 non-small-cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, S Luigi Gonzaga Hospital, Italy
    Oncology (Williston Park) 14:15-9. 2000
    ....
  20. ncbi Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    Giorgio Vittorio Scagliotti
    University of Torino, Department of Clinical and Biological Sciences, S Luigi Hospital, Regione Gonzole, 10, Orbassano Torino, Italy
    J Clin Oncol 26:3543-51. 2008
    ..Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non-small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting...
  21. ncbi Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer
    Silvia Novello
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, University of Turin, Italy
    Lung Cancer 66:327-32. 2009
    ..In the attempt to optimize the efficacy of chemotherapy in advanced non-small cell lung cancer (NSCLC) several strategies need to be investigated including the use of non-platinum combinations and the sequential use of different agents...
  22. ncbi New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer
    Giorgio Vittorio Scagliotti
    Department of Clinical and Biological Sciences, University of Turin Thoracic Oncology Unit, San Luigi Hospital, Orbassano, Torino, Italy
    Clin Lung Cancer 9:S122-8. 2008
    ..Consequently, the differential expression of TS according to histology might explain the different activity of pemetrexed according to histology, as recently postulated...
  23. ncbi Stereotactic body radiation therapy for lung metastases
    Umberto Ricardi
    Radiation Oncology Department, University Hospital S Giovanni Battista di Torino, Via Genova 3, 10126, Torino, Italy
    Lung Cancer 75:77-81. 2012
    ..Purpose of this study was to evaluate efficacy and tolerability of SBRT in a cohort of patients treated between 2003 and 2009 at our institution...
  24. ncbi Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases
    Paola Cassoni
    Department of Biomedical Sciences and Oncology, University of Turin, Turin, Italy
    Histopathology 55:20-7. 2009
    ..To study caveolin-1 (Cav-1) expression in metastatic lung carcinomas...
  25. ncbi Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer
    S Novello
    Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedaliera S. Luigi, Regione Gonzole 10, 10043 Orbassano, Turin, Italy
    Lung Cancer 34:261-9. 2001
    ..CONCLUSION: In advanced NSCLC, the combination carboplatin-paclitaxel at doses of AUC 6 mg/ml per minute and 225 mg/ml every 3 weeks, is both active and relatively well-tolerated...
  26. ncbi Emerging drugs for mesothelioma
    Giorgio Vittorio Scagliotti
    University of Turin, Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, Regione Gonzole, Orbassano Torino, Italy
    Expert Opin Emerg Drugs 12:127-37. 2007
    ..This review summarizes standard chemotherapy options and focuses on the molecular basis of the newest biologically targeted therapies to be implemented in the near future, in the management of MPM...
  27. ncbi Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone
    S Novello
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
    Ann Oncol 18:903-8. 2007
    ....
  28. ncbi Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study
    Giorgio Vittorio Scagliotti
    Department of Clinical and Biological Sciences, University of Turino, Orbassano, Italy
    J Thorac Oncol 7:1823-9. 2012
    ....
  29. ncbi ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
    P Ceppi
    Thoracic Oncology Unit, Orbassano, Torino, Italy
    Ann Oncol 17:1818-25. 2006
    ..Prospective pharmacogenomic studies represent a research priority in early and advanced NSCLC...
  30. ncbi EGFR pathway in advanced non-small cell lung cancer
    Valentina Merlo
    Department of Medical Oncology, Santa Maria della Misericordia University Hospital, Udine, Italy
    Front Biosci (Schol Ed) 3:501-17. 2011
    ..This article reviews the role of EGFR inhibitors focusing mainly on compounds in phase III clinical development...
  31. ncbi Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial
    Umberto Ricardi
    Department of Medical and Surgical Sciences, Radiation Oncology Unit, University of Torino, S Giovanni Battista Hospital, Via Genova 3, 10126 Torino, Italy
    Lung Cancer 68:72-7. 2010
    ..A longer follow-up is needed in order to establish a correct comparison with surgical series, and to fully ascertain a potential negative impact of SBRT on comorbidities of such a fragile patients population...
  32. ncbi Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer
    G Selvaggi
    Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Torino, Torino, Italy
    Ann Oncol 15:28-32. 2004
    ..We designed a prospective study to test epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC) in resected stage I-IIIA non-small-cell lung cancer (NSCLC) and to correlate overexpression with survival...
  33. ncbi Differentiation-inducing factor-1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and thymidylate synthase mRNAs accumulation
    Andrea Elio Sprio
    Department of Clinical and Biological Sciences, University of Turin, Ospedale San Luigi Gonzaga, 10043 Orbassano, Italy
    Cancer Chemother Pharmacol 69:983-9. 2012
    ....
  34. ncbi Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer
    Alice De Sanctis
    Department of Clinical and Biological Sciences, University of Torino, San Luigi Hospital, Orbassano, Torino, Italy
    Cancer 117:3069-80. 2011
    ..The objective of this review was to describe the major DIPTs associated with antineoplastic agents against nonsmall cell lung cancer to help physicians with this difficult diagnostic challenge...
  35. ncbi Current status of adjuvant chemotherapy in NSCLC
    G V Scagliotti
    Department of Clinical and Biological Sciences, S. Luigi Hospital, Thoracic Oncology Unit, University of Turin, Torino, Italy
    Ann Oncol 17:v62-3. 2006
  36. ncbi Tyrosine kinase signal transduction inhibitors. Clinical trials
    Giorgio Vittorio Scagliotti
    University of Torino, Department of Clinical and Biological Sciences, S Luigi Hospital, Thoracic Oncology Unit, Orbassano, Torino, Italy
    Suppl Tumori 1:S34-6. 2002
  37. ncbi Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, S Luigi Hospital, Italy
    Lung Cancer 50:S18-9. 2005
    ..With its innovative mode of action, proven efficacy, favorable toxicity profile and convenient administration, pemetrexed represents a new therapeutic option for the treatment of advanced NSCLC...
  38. ncbi Perspectives in adjuvant chemotherapy in NSCLC
    Giovanni Selvaggi
    University of Turin, Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, Regione Gonzole 10, 10043 Orbassano Torino, Italy
    Expert Rev Respir Med 1:99-110. 2007
    ..Therefore, efforts should be directed toward the collection of surgical specimens to define biomolecular markers to select patients who will benefit from adjuvant treatments on an individual basis...
  39. ncbi Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
    S Novello
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, University of Turin, Orbassano, Turin, Italy
    Br J Cancer 101:1543-8. 2009
    ..Sunitinib malate (SUTENT) has promising single-agent activity given on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off treatment) in advanced non-small cell lung cancer (NSCLC)...
  40. ncbi Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Turin, Italy
    Ann Oncol 18:x32-41. 2007
    ....
  41. ncbi State of the art in mesothelioma
    G V Scagliotti
    University of Turin, Department of Clinical and Biological Sciences, S. Luigi Hospital, Orbassano (Torino, Italy
    Ann Oncol 16:ii240-5. 2005
  42. ncbi Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers
    S Novello
    University of Turin, Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, Orbassano Turin, Italy
    Ann Oncol 16:1662-6. 2005
    ....
  43. ncbi Prevalence of adrenal incidentaloma in a contemporary computerized tomography series
    S Bovio
    Internal Medicine I, Department of Biological and Clinical Sciences, ASO San Luigi, University of Turin, Italy
    J Endocrinol Invest 29:298-302. 2006
    ..Notwithstanding that our subjects were at increased risk of lung cancer, the rate of adrenal metastases was low. We think that the present results can be generalized even if we may disclose the lack of histological diagnosis...